Back in my mind, I'm asking what if Affymax finds its way to get the drug back to the market in some way. I used to be working with GSK and remembered GSK withdraw a drug called Lotronex for irritable bowel syndrome in less than a year after it was approved. However, GSK soon found out that the fatal colitis was largely associated with some patients with certain risk factors and could still be relatively safely used for other patients. With some safety measures in place, GSK successfully brought back Lotronex to the market (see the story here). With this successful story as an example, I'm sure Affymax management would not simply sit there to pray but is likely actively working to find a way out. Maybe such fatal allergic reactions only happen to some patients but not others and there is still a room for the drug in the market. If this turns out to be true, I think it will easily double the share price of Affymax, given how small Affymax is.